Table 1. The correlation between expression characteristic of CRKL and ABCG2 in GC specimens and GC clinicopathologic features.
| Clinicopathologic parameters | CRKL expression (n=e52) | P * | ABCG2 expression (n=72) | P * | ||
|---|---|---|---|---|---|---|
| Low (n=15) | High(n=37) | Low (n=27) | High(n=45) | |||
| Age (years) | ||||||
| ≤60 | 5 (33%) | 16 (43%) | 0.509 | 14 (51%) | 21 (47%) | 0.808 |
| >60 | 10 (67%) | 21 (57%) | 13 (49%) | 24 (53%) | ||
| Gender | ||||||
| Male | 12 (80%) | 25 (68%) | 0.37 | 15 (56%) | 28 (62%) | 0.625 |
| Female | 3 (20%) | 12 (32%) | 12 (44%) | 17 (38%) | ||
| Diameter (cm) | ||||||
| ≤5 | 12 (80%) | 18 (49%) | 0.038 | 19 (70%) | 18 (40%) | 0.016 |
| >5 | 3 (20%) | 19 (51%) | 8 (30%) | 27 (60%) | ||
| Location | ||||||
| Distal third | 10 (67%) | 23 (62%) | 0.76 | 14 (52%) | 31 (69%) | 0.209 |
| Middle or proximal third | 5 (33%) | 14 (38%) | 13 (48%) | 14 (31%) | ||
| Histologic Classification | ||||||
| Poorly differerntial | 7 (47%) | 22 (59%) | 0.792 | 11 (41%) | 23 (51%) | 0.501 |
| Middle/well differerntial | 4 (25%) | 6 (16%) | 9 (37%) | 8 (18%) | ||
| Signer ring cell cancer | 3 (20%) | 6 (16%) | 3 (11%) | 7 (16%) | ||
| Mucinous asenocainoma | 1 (8%) | 3 (9%) | 4 (11%) | 7 (14%) | ||
| Location invasion | ||||||
| T1, T2 | 6 (40%) | 2 (5%) | 0.002 | 15 (56%) | 13 (29%) | 0.045 |
| T3, T4 | 9 (60%) | 35 (95%) | 12 (44%) | 32 (71%) | ||
| Lymph node metastasis | ||||||
| No | 7 (47%) | 4 (11%) | 0.004 | 14 (52%) | 10 (22%) | 0.019 |
| Yes | 8 (53%) | 33 (89%) | 13 (48%) | 35 (78%) | ||
| TNM stage | ||||||
| I, II | 7 (47%) | 2 (5%) | 0.001 | 15 (56%) | 12 (27%) | 0.023 |
| III, IV | 8 (53%) | 35 (95%) | 12 (44%) | 33 (73%) | ||
CRKL and ABCG2 expression level associated with clinicopathologic features in GC patients, including age, gender, tumor size, tumor location, histologic classification, local invasion, lymph node metastasis and TNM stage. Statistically significance was assessed by Fisher's exact text.